OCA

DRUG3 trials

Sponsors

Intercept Pharmaceuticals, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Conditions

Biliary AtresiaPBCPrimary Biliary Cholangitis

Phase 2

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

TerminatedNCT04594694

Intercept PharmaceuticalsPrimary Biliary Cholangitis

Start: 2019-10-02End: 2025-10-14Updated: 2025-11-17

Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

TerminatedNCT06121375

Intercept PharmaceuticalsBiliary Atresia

Start: 2024-09-02End: 2025-10-21Updated: 2025-10-31

Phase 3

Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis

CompletedNCT06715319

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.PBC

Start: 2021-10-09End: 2024-04-29Updated: 2024-12-04